Viking Therapeutics Inc. (VKTX)
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 28.57 +0.11%
VKTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.63B
- EPS (TTM)
- -$4.67
- Dividend yield
- None
- 52-week range
- 25.77 – 43.15
- Day range
- 28.12 – 29.06
- Volume / Avg
- 5.40M / 3.99M
- Beta
- —
- Shares outstanding
- 127.17M
- Next earnings
- Oct 28, 2026
52-week range
VKTX stock today
Shares of Viking Therapeutics (VKTX) finished higher on Oct 7 at $28.54, a gain of 0.56% or $0.16 per share, versus the S&P 500's 0.22% decline. Shares are 33.9% below their 52-week high of $43.15, set on Nov 12, 2025 and 10.7% above the 52-week low of $25.77, near the bottom of the past year's range. VKTX is down 18.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 9.5%.
Viking Therapeutics has posted a net loss over the last twelve months (EPS of -$4.67), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 28; analysts expect EPS of $1.00.
Summary generated from market data by MetaCap's automated system. Methodology
About Viking Therapeutics
Company profileViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Brian Lian Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 65
- IPO year
- 2015
- Website
- vikingtherapeutics.com
Analyst forecast
ForecastConsensus (20 analysts)
strong_buy
Avg. price target
$94.71+231.85%
- Strong buy 5
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 28, 2026
- EPS estimate
- $1.00
VKTX news
All VKTX news- VKTX Advances Obesity Program With New Oral Maintenance StudyNasdaqVKTX, NVO, LLY
- VKTX Down 16% in a Month: Time to Invest or Exit the Stock?NasdaqVKTX, NVO, LLY
- Here Are My Top 4 Stocks to Buy in OctoberNasdaqVKTX, GOOGL, MELI, GOOG
- 3 Non-AI Growth Stocks That Have Massive UpsideNasdaqVKTX, TTWO, FIVE
- Stocks Settle Mixed as Chipmakers Climb and Financial Stocks FallNasdaqMPC, SNDK, JPM, VICR
- Stocks Supported as Crude Oil Prices EaseNasdaqALK, SAIA, UAL, MPC
- Stocks Mixed as Crude Oil Prices and Financial Stocks FallNasdaqC, SNDK, JPM, VICR
Viking Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs VKTX |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs VKTX |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs VKTX |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs VKTX |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs VKTX |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs VKTX |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs VKTX |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs VKTX |
Indexes, lists and sector
Viking Therapeutics stock FAQ
What is Viking Therapeutics's stock price today?
VKTX last traded at $28.54 as of Oct 7, 4:00 PM EDT, up 0.56% on the day. Prices are delayed at least 15 minutes.
When is Viking Therapeutics's next earnings date?
Viking Therapeutics is expected to report earnings on Wednesday, October 28, 2026. Analysts expect EPS of $1.00.
Who is Viking Therapeutics's CEO?
Dr. Brian Lian Ph.D. is the chief executive officer of Viking Therapeutics Inc., which has about 65 employees.
What is the VKTX 52-week high?
The 52-week high for VKTX is $43.15 and the 52-week low is $25.77. The stock is currently 33.9% below its high.